Research.Patient.info
Relapsed/Refractory Small Cell Lung Cancer research hub
2 indexed studies · 0 currently recruiting
- active not recruitingPHASE2
A Phase 2 Study of Tarlatamab in Patients With Small Cell Lung Cancer (SCLC)
This study is testing a new medicine called tarlatamab for people with a type of lung cancer called Small Cell Lung Cancer (SCLC) that has come back or not responded to previous treatments. It aims to see how safe and effective the new medicine is.
United States · Austria · Belgium - authorisedPhase I and Phase II (Integrated)- First administration to humans
A Phase 1/2 Study of BMS-986525 as Monotherapy and in Combination with Nivolumab in Participants with Relapsed/Refractory Small Cell Lung Cancer
This study is testing a new drug, BMS-986525, for people with small cell lung cancer that has come back or not responded to previous treatments. It's looking to see how safe the drug is, what side effects it might cause, and how well it works, both alone and when given with another medicine called nivolumab.
Italy · Spain · Romania